Investor profile
Michael Rosenblatt
Accelerator, Venture capital & Senior Partner at Flagship Pioneering, Advisory Partner at Ascenta Capital
Michael Rosenblatt works as an Advisory Partner at Ascenta Capital. The firm's known portfolio counts 9 companies.
Is Michael Rosenblatt a fit for your startup?
Paste your website. AI checks the fit and scores every other investor too.
Investment focus
Contacts
Affiliated funds' portfolios
Senior Partner at Flagship Pioneering, whose known portfolio counts 9 companies
- Lila Sciences
- Harbinger Health
- Ampersand Biomedicines
- Etiome
- Expedition Medicines
- Extuitive
- Foghorn Therapeutics
- Serif Biomedicines
- Terrana Biosciences
Advisory Partner at Ascenta Capital, whose known portfolio counts 9 companies
- Iambic
- Tubulis
- Odyssey Therapeutics
- Angitia Biopharmaceuticals
- Triana Biomedicines
- Alpha-9 Oncology
- Cardurion Pharmaceuticals
- OrsoBio
- ADARx Pharmaceuticals
Investor Profile
Michael Rosenblatt is listed against sectors AI, Climate, Food and Healthcare, and focus areas AgriTech, Biotech, Drug Discovery and FoodTech in the database.
Ascenta Capital appears in Growth, Late-Stage and Seed rounds across its known deals.
The firm portfolio and the focus above give founders context on whether Michael Rosenblatt matches their raise.
Colleagues
Showing 20 of 48
Margo Georgiadis
CEO/Partner
San Francisco, United States
Hok Hei Tam
Science Partner
Cambridge, United States
Avak Kahvejian
General Partner
Cambridge, United States
Ignacio Martinez
General Partner
Boston, United States
Ajit Singh
CEOPartner
Palo Alto, United States
Jason Park
Partner
Cambridge, United States
Geoffrey von Maltzahn
General Partner
Cambridge, United States
Bernard Cooney
Senior Partner
Cambridge, United States
Jacob Rubens
Origination Partner
Cambridge, United States
Stephen Berenson
Advisor Partner
United States
Torben Straight Nissen
Executive Partner
Boston, United States
Guillaume Pfefer
CEO Partner Senda Biosciences
Boston, United States
Marie Yurkovich
Biotech Company Creation
New York City, United States
Sophie de Boer
Senior Principal
Cambridge, United States
Alex Goldsmith
Vice President, Global Scientific Engagement
Cambridge, United States
Nathan Stebbins
Senior Principal
Los Angeles, United States
Ewen Cameron
Operating Partner
Boston, United States
Olivia Arnold
Venture Creation Associate
Boston, United States
Murillo Silva
Senior Associate in Venture Creation
Boston, United States
Young Guang
Investor
Boston, United States
Frequently asked questions
Who is Michael Rosenblatt?
Michael Rosenblatt is an accelerator partner and venture capital investor based in Newton Highlands, Massachusetts, United States, listed as Advisory Partner at Ascenta Capital. The known portfolio of that firm counts 9 companies. That portfolio belongs to the firm, not to Michael Rosenblatt personally.
What does Michael Rosenblatt invest in?
Listed sectors include AI, Climate, Food and Healthcare; listed focus areas include AgriTech, Biotech, Drug Discovery and FoodTech. Those tags come from the portfolios of the firms this profile is attached to, so they read as a record of what has been backed rather than a stated preference for what comes next.
What stage does Michael Rosenblatt invest at?
Ascenta Capital appears in Growth, Late-Stage and Seed rounds across its known deals, and Michael Rosenblatt is listed there as Advisory Partner. Stage is the strongest single filter when you build a target list: an investor with no record at your stage rarely starts with you.
Which firm is Michael Rosenblatt listed at?
Michael Rosenblatt is listed as Advisory Partner at Ascenta Capital. 48 other people in the database share a firm with Michael Rosenblatt.
How do I contact Michael Rosenblatt?
An email address, a phone number and a LinkedIn page are on file for Michael Rosenblatt. The address stays masked on this page and is readable inside RaiseHunt after you create an account.
Skip the browsing. Let AI find your ideal investors in one minute.
Paste your startup website and AI picks your best-fit investors out of 135,000+ profiles.
Data: RaiseHunt investor dataset · Snapshot 5 September 2026 · How this data is built · Report a correction or request removal